+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Breaking news in spinal cord injury research: FDA approved phase I clinical trial of human, autologous schwann cell transplantation in patients with spinal cord injuries

Breaking news in spinal cord injury research: FDA approved phase I clinical trial of human, autologous schwann cell transplantation in patients with spinal cord injuries

Neural Regeneration Research 7(22): 1685-1687

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 057324114

Download citation: RISBibTeXText

PMID: 25624788

Related references

From transplanting Schwann cells in experimental rat spinal cord injury to their transplantation into human injured spinal cord in clinical trials. Progress in Brain Research 231: 107-133, 2017

Clinical translation of autologous Schwann cell transplantation for the treatment of spinal cord injury. Current Opinion in Organ Transplantation 18(6): 682-689, 2013

Phase 1 Trial of Autologous Bone Marrow Stem Cell Transplantation in Patients with Spinal Cord Injury. Stem Cells International 2016: 6768274, 2016

Safety of Autologous Human Schwann Cell Transplantation in Subacute Thoracic Spinal Cord Injury. Journal of Neurotrauma 34(21): 2950-2963, 2017

A clinical trial report of autologous bone marrow-derived mesenchymal stem cell transplantation in patients with spinal cord injury. Experimental and Therapeutic Medicine 6(1): 140-146, 2013

Breaking bad news in spinal cord injury; a qualitative study assessing the perspective of spinal cord injury survivors in Turkey. Journal of Spinal Cord Medicine: 1-8, 2017

172 A Phase I, Open-Label, Single-Site, Safety Study of Human Spinal Cord-Derived Neural Stem Cell Transplantation for the Treatment of Chronic Spinal Cord Injury. Neurosurgery 63 Suppl 1(): 168-169, 2016

Treatment of chronic thoracic spinal cord injury patients with autologous Schwann cell transplantation: an interim report on safety considerations and possible outcomes. Neuroscience Letters 443(1): 46-50, 2008

Human umbilical cord-derived Schwann-like cell transplantation combined with neurotrophin-3 administration in dyskinesia of rats with spinal cord injury. Neurochemical Research 36(5): 783-792, 2011

Safety and possible outcome assessment of autologous Schwann cell and bone marrow mesenchymal stromal cell co-transplantation for treatment of patients with chronic spinal cord injury. CytoTherapy 15(7): 782-791, 2013

Schwann cell-like remyelination following transplantation of human umbilical cord blood (hUCB)-derived mesenchymal stem cells in dogs with acute spinal cord injury. Journal of the Neurological Sciences 300(1-2): 86-96, 2011

Human Neural Stem Cell Transplantation in Chronic Cervical Spinal Cord Injury: Functional Outcomes at 12 Months in a Phase II Clinical Trial. Neurosurgery 64(Cn_suppl_1): 87-91, 2017

A Phase III Clinical Trial Showing Limited Efficacy of Autologous Mesenchymal Stem Cell Therapy for Spinal Cord Injury. Neurosurgery 78(3): 436-47; Discussion 447, 2016

Spinal cord injury treatment with intrathecal autologous bone marrow stromal cell transplantation: the first clinical trial case report. Journal of Trauma 64(1): 53-59, 2008

Treatment of spinal cord injury with co-grafts of genetically modified Schwann cells and fetal spinal cord cell suspension in the rat. Neurotoxicity Research 7(1-2): 169-177, 2005